Growth Hormone Deficiency and Diabetes Insipidus as a Complication of Endoscopic Third Ventriculostomy

Tafuri, Kimberly; Wilson, Thomas A.

doi:10.4274/jcrpe.801

Cited by 6 publications

(4 citation statements)

References 12 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diabetes insipidus was reported in 0.64% of cases, weight gain in 0.27%, and precocious puberty in 0.04% 6) . Additionally, amenorrhea and partial growth hormone deficiency were reported due to hypothalamic injury 17 , 26) .…”

Section: Complications Of Endoscopic Third Ventriculostomymentioning

confidence: 99%

Prevention of Complications in Endoscopic Third Ventriculostomy

Jung

Chong

Kim

et al. 2017

J Korean Neurosurg Soc

View full text Add to dashboard Cite

A variety of complications in endoscopic third ventriculostomy have been reported, including neurovascular injury, hemodynamic alterations, endocrinologic abnormalities, electrolyte imbalances, cerebrospinal fluid leakage, fever and infection. Even though most complications are transient, the overall rate of permanent morbidity is 2.38% and the overall mortality rate is 0.28%. To avoid these serious complications, we should keep in mind potential complications and how to prevent them. Proper decisions with regard to surgical indication, choice of endoscopic entry and trajectory, careful endoscopic procedures with anatomic orientation, bleeding control and tight closure are emphasized for the prevention of complications.

show abstract

Section: Complications Of Endoscopic Third Ventriculostomymentioning

confidence: 99%

Prevention of Complications in Endoscopic Third Ventriculostomy

Jung

Chong

Kim

et al. 2017

J Korean Neurosurg Soc

View full text Add to dashboard Cite

show abstract

“…Several single-case studies have reported electrolyte or single-parameter endocrine abnormalities (diabetes insipidus and secondary amenorrhea) after ETV [3,35,36,37,38,39,40,41,42,43,44,45] (table 1). Goumnerova and Frim [3] reported 1 patient who developed a transient increase in thirst and appetite that resolved within 3 months after ETV complicated by intraoperative transient bradycardia; the endocrine evaluation was normal.…”

Section: Discussionmentioning

confidence: 99%

“…Although ETV is thought to be safe, various complications due to damage to neural and vascular structures have been reported [4,9,11,15,16,19,28,29,30,31,32,33]. Injury to the hypothalamic-pituitary axis, followed by clinically relevant endocrine sequelae, has been rarely described in the literature [4,28,34,35,36,37,38,39,40,41,42,43,44,45]. …”

Section: Case Reportmentioning

confidence: 99%

Amenorrhea after Endoscopic Third Ventriculostomy for a Failed Shunt in Spina Bifida: Case Report and Review of the Literature

Spacca¹,

Danti²,

Taverna³

et al. 2015

Pediatr Neurosurg

View full text Add to dashboard Cite

Background: Secondary endoscopic third ventriculostomy (ETV) for the management of shunt failure may be efficacious, though it may be followed by more frequent complications (including endocrinological impairment, e.g. amenorrhea) compared to primary ETV. These complications are usually underreported in the literature. Aim: We report a case of secondary amenorrhea after ETV for the management of shunt failure in a young woman with hydrocephalus associated with myelomeningocele. Methods: A 25-year-old woman affected by hydrocephalus and myelomeningocele was admitted for secondary ETV for the management of shunt failure. The endoscopic procedure was preferred over shunt revision based on good results of secondary ETV, especially in patients with hydrocephalus associated with Chiari II malformation and spina bifida. Results: Despite the surgery being uneventful, the patient had early (postoperative seizure) and late (secondary amenorrhea) complications. In the early postoperative period, she received external ventricular drainage followed by VP shunt reimplantation 2 weeks later. There was no neurological morbidity, but 1 month after the ETV she reported secondary amenorrhea and weight gain. Laboratory investigations ruled out hyperprolactinemia, which had been treated with cabergoline administration with no efficacy since the patient was still without regular periods 1 year later. Conclusion: ETV may be followed by endocrinological complications like amenorrhea that are rarely reported.

show abstract

“…Pioglitazone function as insulin sensitizer and thus, enhance the insulin action and improve hyperglycemia in patients with T2DM [10]. TZDs have also been shown to decrease pancreatic β cell destruction and therefore have a potential role in the treatment and prevention of T1DM [11].…”

Section: Introductionmentioning

confidence: 99%

"The effects of a new chromenyl-methylenethiazolidine-2,4-dione in alleviating oxidative stress in a rat model of streptozotocin induced diabetes "

Chis¹,

Clichici²,

Simedrea³

et al. 2018

Studia UBB Chemia

View full text Add to dashboard Cite

Type 1 diabetes mellitus (T1DM) is caused by the insulin deficiency resulting from the progressive destruction of pancreatic β cells. Thiazolidine-2,4-diones (TZDs) activate the peroxisome proliferator-activated receptor-γ (PPARγ) and enhance the actions of insulin. 5-((6-methyl-4-oxo-4Hchromen-3-yl)methylene)-3-(2-(4-nitrophenyl)-2-oxoethyl)-thiazolidine-2,4-dione (TZDd) is a heterocyclic derivative synthesized in our laboratory. The purpose of this study was to examine whether TZDd has hypoglycemic and antioxidant effects in diabetic rats. Its effects were compared with those of quercetin (Que), a potent antioxidant, and with pioglitazone (Pio), a well-known antidiabetic drug. Type 1 DM was induced in Wistar rats by the intraperitoneal administration of streptozotocin (STZ) (60 mg/kg). The non-diabetic and diabetic rats were treated with Que (30 mg/kg/day), pioglitazone (30 mg/kg/day), or TZDd (30 mg/kg/day), for 5 weeks. The serum levels of malondialdehyde (MDA) and protein carbonyl (PC) groups, and the superoxide dismutase (SOD) and catalase (CAT) activities in the blood were then assessed. The results indicated that the TZDd decreased the blood oxidative stress parameters in the treated diabetic rats, compared to Que and pioglitazone. In conclusion, the hypoglycemic and antioxidant effects of TZDd in diabetic rats, suggest its therapeutic properties for the clinical treatment of T1DM.

show abstract

Growth Hormone Deficiency and Diabetes Insipidus as a Complication of Endoscopic Third Ventriculostomy

Cited by 6 publications

References 12 publications

Prevention of Complications in Endoscopic Third Ventriculostomy

Prevention of Complications in Endoscopic Third Ventriculostomy

Amenorrhea after Endoscopic Third Ventriculostomy for a Failed Shunt in Spina Bifida: Case Report and Review of the Literature

"The effects of a new chromenyl-methylenethiazolidine-2,4-dione in alleviating oxidative stress in a rat model of streptozotocin induced diabetes "

Contact Info

Product

Resources

About